Alfonso Dueñas‐González

Author

Instituto Nacional de Cancerología ORCID

Also Known As

A Dueñas-Gonzalez, A Dueñas-González, A. DUEÑAS-GONZÁLEZ, A. Duenas-Gonzalez, A. Duenas-González, A. Dueñas-Gonzalez, A. Dueñas-Gonzàlez, A. Dueñas-González, A. Dueñas‐Gonzalez, A. Dueňas-González

239

Publications

8.2K

Citations

H-Index

116

Concepts

All Affiliations

Instituto Nacional de Cancerología Universidad Nacional Autónoma de México Instituto Nacional de Cancerología Universidad de Cuautitlán Izcalli Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

About

Alfonso Dueñas‐González is an author at Instituto Nacional de Cancerología specializing in medicine, oncology, and cervical cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	40	2.5K
2	Public Health	11	11	901
3	Health Sciences	6	6	284
4	Natural Sciences	3	3	151
5	Engineering	1	1	22

Alfonso Dueñas‐González

Publications

5.9K

Citations

H-Index

Page 1

	Year	Citations
Planning cancer control in Latin America and the Caribbean Paul E. Goss, Brittany Lee, Tanja Badovinac-Črnjević, The Lancet Oncology Preventive MedicineMedicineGlobal HealthEpidemiology Of CancerCancer Prevention	2013	496
Phase III, Open-Label, Randomized Study Comparing Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Patients With Stage IIB to IVA Carcinoma of the Cervix Alfonso Dueñas‐González, Juan José Zarbá, Firuza D. Patel, Journal of Clinical Oncology	2011	468
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors Myrna Candelaria, Dolores Gallardo‐Rincón, Claudia Arce, Annals of Oncology Chemotherapy ResistanceMedicinePharmacologyMagnesium ValproatePharmacotherapy	2007	249
Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Blanca Segura-Pacheco, Catalina Trejo‐Becerril, Enrique Pérez‐Cárdenas, PubMed	2003	206
Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline Linus Chuang, Sarah Temin, Rolando Camacho, Journal of Global Oncology	2016	192
The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. Mandy Juárez, Alejandro Schcolnik‐Cabrera, Alfonso Dueñas‐González PubMed	2018	184
Ether a go-go Potassium Channels as Human Cervical Cancer Markers Luz María Barajas Farias, Deysi Bermúdez Ocaña, Fernando Larrea, Cancer Research	2004	157
A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes Pilar Zambrano, Blanca Segura-Pacheco, Enrique Pérez‐Cárdenas, BMC Cancer	2005	150
A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer Claudia Arce, Carlos Pérez‐Plasencia, Aurora González‐Fierro, PLoS ONE	2006	144
Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines Alma Chávez‐Blanco, Carlos Pérez‐Plasencia, Enrique Pérez‐Cárdenas, Cancer Cell International	2006	142

Page 1